Advances in Ophthalmology and Optometry

About Advances in Ophthalmology and Optometry

Advances in Ophthalmology and Optometry: Journal Profile

Advances in Ophthalmology and Optometry is an annual review publication from Elsevier that surveys the year's most important findings and updates across ophthalmology and optometry, so that practising clinicians can improve patient outcomes with current, clinically usable information. Its ISSN, the identifier carried in this JournalsWorld record and printed on Elsevier's own subscription page, is 2452-1760; OpenAlex additionally associates the identifier 2950-452X with the same source record. Elsevier's shop describes the publication plainly: one volume and one issue per year. A distinguished editorial board, led by Dr Myron Yanoff, identifies the key areas of major progress and controversy in the field and invites preeminent specialists to contribute original review articles devoted to those topics, bringing concepts to a clinical level and exploring their everyday impact on patient care. That formula, an annual, editor-curated synthesis of a fast-moving clinical field, is the defining feature of this title, and it explains both its format and its audience: ophthalmologists and optometrists in practice, and the trainees who support them, who need the year's developments distilled by experts rather than another venue for primary research reports.

The publication belongs to a recognisable Elsevier family of annual Advances volumes, in which a specialty's year is reviewed in a single hardback-sized volume of roughly 240 pages. The volumes are sold both as a continuing subscription, under the journal ISSN, and as individual annual books with their own ISBNs, a dual identity that can confuse directory records: the 2016 volume appeared in August and October listings of that year, the 2021 volume is catalogued as the sixth volume in the series, and volumes for 2022, 2023 and 2025 are each listed by Elsevier Health with their own ISBNs, page counts of about 240 pages and the same editorial leadership. The first volume is dated 2016 in the publisher's and bibliometric records, and a new volume has appeared annually since, which matches the coverage span, 2016 to 2025, carried in this record and in OpenAlex. Anyone citing the title should therefore cite it the way its publisher presents it, by year and volume, and should expect library holdings to be split between journal-style shelving under the ISSN and book-style cataloguing under each year's ISBN.

Editorial Leadership

The series is headed by Myron Yanoff, MD, Professor and Chair of the Department of Ophthalmology at Drexel University College of Medicine and Adjunct Professor of Ophthalmology at the University of Pennsylvania, in Philadelphia. Elsevier's volume pages credit Dr Yanoff consistently across the run, from the first volume to the 2025 volume, and describe the working method that his board follows: identify the key areas of major progress and controversy, then invite the specialists best placed to write about them. The named contributor lists for individual volumes show the breadth that method produces. The first volume's authors, for example, spanned ophthalmic pathology and ocular oncology, cataract surgery, glaucoma, neuro-ophthalmology, oculoplastics, uveitis, paediatrics, optometry and vitreoretinal disease, a roster that mirrors the section structure the series settled into. For readers, the continuity of editorship matters because an annual review lives or dies by its editor's judgement about what counted in a given year; a single, long-serving editor gives the series a stable sense of its audience and its standards, and makes year-on-year comparison of coverage meaningful.

Scope and Contents

The scope is the whole of clinical ophthalmology and optometry, organised by subspecialty. The 2021 volume's contents, as the publisher lists them, were broken into sections on Optometry, Cataracts, Pediatrics, Ophthalmic Pathology and Ocular Oncology, Vitreoretinal Disease, Glaucoma, Neuro-ophthalmology, Oculoplastics and Uveitis, and that architecture is representative of the series as a whole. The 2023 volume contained 30 articles, on topics the publisher highlights as conjunctival tumours in children, regulation as a glaucoma therapeutic, nasolacrimal duct obstruction, blepharospasm and virtual perimetry. The 2025 volume contained 26 articles, including socio-economic factors in pediatric ophthalmology, sustainability in cataract surgery, examining carbon emissions and waste from the operating room, thyroid eye disease from a neuro-ophthalmology perspective, global outreach in oculoplastics, and artificial intelligence in pediatric ophthalmology and retinal imaging. Read together, those contents pages show the series' editorial instincts: core clinical updates in the major subspecialties, mixed with the cross-cutting questions, about technology, equity, sustainability and global delivery of eye care, that are reshaping practice.

The OpenAlex topic profile, built from the publication's 341 indexed works, corroborates that scope from the citation side. Its largest topic clusters are retinal diseases and treatments, intraocular surgery and lenses, ophthalmology and visual impairment studies, corneal surgery and disorders, and ocular oncology and treatments, each accounting for roughly fifty of the indexed items. In other words, the back catalogue is weighted toward the surgical and retinal heartland of ophthalmology, while the recent volumes' highlighted topics show the optometric, paediatric and public-health sides of the title receiving deliberate editorial attention. Authors and readers should note what kind of writing the series publishes: these are commissioned, in-depth clinical reviews that synthesise and distil the latest research and practice guidelines into timely, topic-based overviews, in the publisher's own words. It is not a venue for unsolicited case reports or original trial data, and its Guide for Authors and latest articles are presented by the publisher through ScienceDirect, where the journal's home sits within Elsevier's journal programme.

Recognition, Indexing and Metrics

The 2023 volume carries a distinction the publisher records on its own page: it was named to Doody's Core Titles 2024 in Optometry. Doody's core title lists are used by medical librarians to build clinical collections, so the commendation is best read as evidence of the series' standing with its intended audience of practising clinicians and the libraries that serve them, which is precisely the audience an annual clinical review must convince. Bibliometrically, the verified figures for this profile come from OpenAlex, resolved through the ISSN record (source S2898386384). OpenAlex records 341 works for Advances in Ophthalmology and Optometry, of which 46 are recorded as open access, cited 559 times in total, giving an h-index of 10, an i10-index of 12 and a two-year mean citedness of about 0.18, with coverage from the first volume in 2016 through 2025 and the publisher recorded as Elsevier BV, in the United States listing carried in this record. OpenAlex also classifies the source as a core source in its listing data.

Those numbers need the interpretation this profile gives all annual-review metrics. A once-a-year publication accumulates documents slowly, and its reviews are written to be used in clinics and teaching rather than to maximise citation velocity, so modest citation densities are the norm for the genre and say little about clinical usefulness. The h-index of 8 shown in the earlier version of this JournalsWorld record, and in aggregators drawing on other databases, differs from the OpenAlex figure of 10 by the ordinary mechanism of differing document and citation coverage; both describe the same small, steadily cited body of review literature. No Journal Impact Factor from Clarivate could be verified for this title from the sources consulted for this profile, and none is claimed here. OpenAlex does carry article processing charge pricing for the source, listing an APC figure of 2,800 US dollars recorded for 2021, which most plausibly reflects an optional open-access route within Elsevier's systems rather than a condition of appearing in this commissioned series; because the figure could not be confirmed against a current author-facing page for this title in the sources consulted, readers should treat any charge as a matter to verify directly with the publisher, and this profile makes no claim that publishing here requires it. A listing in the Directory of Open Access Journals could not be verified in the DOAJ search performed for this profile, which is consistent with the title's identity as a subscription annual rather than an open-access journal.

Who Should Read It, and How to Use It

The series is written for ophthalmologists and optometrists who need the current clinical information required to improve patient outcomes, and its reviews are designed to be actionable: concepts are brought to a clinical level, and their everyday impact on patient care is explored explicitly. For a practising clinician, the natural use is an annual structured update, reading across one's own subspecialty in depth and across neighbouring subspecialties for the developments that change referral, co-management and counselling decisions. For residents and fellows, the volumes serve as a bridge between textbook knowledge and the current literature, with each article synthesising a topic's recent evidence and controversies under a named specialist's authorship. For optometrists, the inclusion of optometry as a standing section, and the Doody's recognition in optometry for the 2023 volume, mark the series as one of the few ophthalmic annuals that addresses both professions named in its title rather than treating optometry as an afterthought.

Practical guidance follows from the publication model. Because content is commissioned by the editorial board around the year's chosen topics, prospective contributors should not submit unsolicited manuscripts on the assumption of a conventional journal pipeline; the route into the series is editorial invitation, and specialists who wish to be considered are best served by visibility in the subspecialty community the board draws on. Readers seeking a specific topic should search by year as well as by subject, since coverage rotates: a topic treated in depth in one volume may not recur for several years, and the ScienceDirect journal home and the publisher's volume pages are the authoritative places to check what the latest volume contains. Librarians should catalogue with both identities in view, the continuing ISSN 2452-1760 and the annual ISBNs, so that holdings are not split into apparently different titles. Handled that way, Advances in Ophthalmology and Optometry is exactly what its publisher promises: a disciplined, expert-edited annual account of where eye care has moved, and of what that movement means at the clinic door.

A Decade of Volumes, 2016 to 2025

The run of volumes itself is evidence worth reading carefully. Elsevier's listings show a first volume in 2016, edited by Dr Yanoff with a contributor group whose affiliations map the series' intended territory, and then an unbroken annual sequence: third volume in 2018, sixth volume in 2021, and further volumes in 2022, 2023 and 2025, each presented as a self-contained annual of roughly 240 pages and each also offered in electronic book form. Reviewers of the early volumes, in a commendation the publisher carries, described the series as a comprehensive volume that they would recommend to ophthalmology residents in training, to general ophthalmologists and to optometrists, which is a precise statement of the three audiences the title has continued to serve. The stability of the format across a decade is part of the product: subscribers know that each year will bring one volume, organised by subspecialty, written by invited specialists, and sized for reading rather than for shelving unread. In a field where the primary literature grows faster than any clinician can follow, that predictability is the service being sold, and the subscription page's simple statement of one volume and one issue a year is therefore the most important bibliographic fact in this profile after the ISSN itself.

The decade also shows the field changing inside the series' covers. The earliest volumes concentrated on the established subspecialty agenda, while the highlighted contents of the 2023 and 2025 volumes add virtual perimetry, telemedicine-era assessment, artificial intelligence applied to retinal imaging and to paediatric ophthalmology, the carbon footprint and waste of cataract surgery, socio-economic factors in children's eye care and global outreach in oculoplastic surgery. That drift mirrors ophthalmology's own movement, from a purely surgical and imaging frontier toward questions of delivery, equity and environmental cost, and it is visible here precisely because an annual review must, by design, declare each year what it takes the year's important developments to have been. Scholars of the specialty's recent history could do worse than to read the series' contents pages as a primary source: ten years of editorial choices about what mattered, made by a stable board, in a consistent format.

The Annual Review Model, and Its Limits

It is worth stating plainly how this title differs from the journals with which directory listings group it. A conventional journal receives manuscripts, sends them for peer review and publishes accepted work continuously or in frequent issues; its quality signals are its acceptance practices, its indexing and its citation record. An annual review of the Elsevier Advances type inverts most of that: the editor commissions the contents, the authors are invited specialists, the unit of publication is the year, and the quality signal is the editor's and contributors' standing and the usefulness of the synthesis to clinicians. Judged by journal criteria alone, such a title can look anomalous: it has an ISSN and a ScienceDirect journal home, yet it is also a book series with ISBNs; its citation counts are modest, yet its volumes are stocked and recommended by medical libraries; it publishes no unsolicited research, yet it shapes practice by deciding which research clinicians hear about. None of those anomalies is a defect. They are the ordinary features of the annual-review genre, and readers who understand the genre will use the title well, as a curated synthesis to read, teach from and cite for the state of a topic in a given year, rather than as a venue whose metrics should be compared line by line with monthly research journals.

Two cautions complete the picture. First, because the contents are commissioned, the absence of a topic from recent volumes proves nothing about that topic's importance; it may simply not have been that topic's year, and researchers should pair the series with primary databases for systematic work. Second, bibliographic records for the series are unusually easy to corrupt, because the same content is described as a journal by subscription systems, as books by trade catalogues and as a source by citation databases, each with its own dates and identifiers. This profile has therefore anchored every claim to the publisher's own pages and to the ISSN-resolved OpenAlex record, and has treated the earlier directory values in this JournalsWorld record, including a numeric code in the publisher field and an h-index drawn from a different database, as the data errors and cross-database artefacts they are. The corrected essentials are simple: Elsevier publishes it, Dr Yanoff's board edits it, it appears once a year under ISSN 2452-1760, and it has done so since 2016.

One further practical note concerns timing and expectations for readers who follow the series through a subscription. Because each volume is a single annual issue, a development published in the primary literature just after a volume closes will ordinarily wait for the following year's volume to receive the series' full review treatment, and the board's topic choices should be read with that lag in mind. The compensating strength is depth and stability: an article in this series is written once the year's evidence has settled enough to be judged, by an author chosen for standing in the topic, and it remains the series' considered account of that topic until a later volume revisits it.

Frequently Asked Questions

What is Advances in Ophthalmology and Optometry? An annual Elsevier review publication, ISSN 2452-1760, that reviews the year's most important findings and updates in ophthalmology and optometry for practising clinicians. Earlier versions of this record showed a numeric code in place of the publisher's name; that was a data error, and the publisher is Elsevier.

How often does it appear? Once a year: one volume, one issue annually, beginning with the 2016 volume and continuing through the 2025 volume in the records verified for this profile, each volume running to about 240 pages.

Who edits it? An editorial board led by Dr Myron Yanoff, Professor and Chair of Ophthalmology at Drexel University College of Medicine and Adjunct Professor of Ophthalmology at the University of Pennsylvania, who invites preeminent specialists to write each volume's reviews.

What does it cover? All major areas of clinical ophthalmology and optometry, organised by subspecialty, including optometry, cataracts, pediatrics, ophthalmic pathology and ocular oncology, vitreoretinal disease, glaucoma, neuro-ophthalmology, oculoplastics and uveitis, plus cross-cutting topics such as artificial intelligence in retinal imaging and sustainability in cataract surgery.

What are its metrics? OpenAlex records 341 works, 559 citations, an h-index of 10 and an i10-index of 12 under its ISSN record. Figures in other databases differ because their coverage differs.

Can I submit a manuscript? The series works by editorial commission: the board identifies the year's key topics and invites specialists to write them. The publisher presents the title's Guide for Authors and latest articles through ScienceDirect, which is the authoritative route for current guidance.